Ugarte MD, Ugarte SJC, Piñera MJ, Jordán GJ

Language: Spanish
References: 21
Page: 195-202
PDF size: 131.03 Kb.

ABSTRACT

Introduction. The incidence of the intracranial primitive tumors is about 1 to 12 cases for 100 000 inhabitants per year. The most frequent tumors are gliomas that include tumors like astrocitomas benign and malignant. Methods. We studied twenty nine patients who were sent to Medical Surgical Research Center to make a magnetic resonance with spectroscopy, in a period of 18 months. The histological result was obtained by biopsy or autopsy. Results. Twenty patients were male, mean age of 45.8 ± 17.2 years, 23 (79.3%) were of white color. Of the 29 tumors, 10 were glioblastomas, 9 high grade gliomas and 10 low grade gliomas. Conclusions. This results allows us to affirm the utility of the magnetic resonance and the spectroscopy in the diagnosis of the cerebral tumors.

REFERENCES

1. Pedrosa C. Diagnóstico por Imagen. Volumen 2. Madrid: Editorial Mc Graw- Hill; 1992. p. 1606- 1612.

2. Baltzer T. Contrast Agents for MR Imaging . Germany: Ed Springer; 2003. p. 53-63.

3. Ugarte JC, Banasco J, Ugarte D. Manual de Imagenología Médica. C. Habana: Editorial Ciencias Médicas; 2000.p.25-9.

4. Mukhevji SK. Clinical Applications of Magnetic Resonance Spectros copy. Germany: Edit Wiley- Liss; 1998.p.301-21.

5. Ricci P. Effect of voxel position on single - voxel MRS finding. AJNR 2000:21: 367-374.

6. Smith JK, Kwock L, Castillo M. Effects of contrast material on single volume prot on MR spectroscopy. AJNR 2000;21:1084-89.

7. Castillo M, Kwock L, Mukherji S. Clinical application of proton MR spectroscopy. AJNR 1996;17:1-15.

8. Schwartz RB. Neuroradiology of brain tumors. Neurol Clin 1995; 13:723-56.

9. Pérez-Gómez M, Junque C, Mercader JM. A plicaciones de la espectroscopia por resonancia magnética en el estudio de la patología cerebral. Rev Neurol 2000;30(2):155-60.

10. Leclerc X, HuismN T, Sorensen G. The potential of proton magnetic resonance spectroscopy (1H-MRS) in the diagnosis and managemen t of patients with brain tumors. Cur Op Oncol 2002;14(3): 292-8.

11. Mbller-Hartmann W, Hermingaus S, KringsT. Clinical application of proton magnetic resonance spectroscopy: N -acetyl-aspartate, creatine and choline, NMR Bromed 1999;4:47-52.

12. Smith JK, Castillo M, Kwock L. MR spectroscopy of brain tumors. Magnetic Reson Imaging Clín N Am 2003;2:415 -25.

13. Miller BL. A review of chemical issues in 1HNMR spectroscopy: N acetyl -aspartate, creatine and cholíne. NMR Blomed 1991;4:47 -52.

14. Castillo M, Kwock L, Mukher ji SK. Clinical applications of MR spectroscopy. AJNR 1996;17:1-15.

15. Moller-Hartmann W, Herminghaus S, Krings T. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 2002;44:371-81.

16. Howe FA, Barton SJ, Cudlip SA. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spe ctroscopy. Magn Reson Med 2003;49:223-32.

17. Castillo M, Smith JK, Kwock L. Correlation of myo -inositol levels and grading of cerebral astrocytomas. AJNR 2000;21:1645 -49.

18. Barba I, Cabanas ME, Arus C. The relationship between nuclear magnetic resonance - visible lipids, lipid droplets, and cell proliferation in cultured C6 cells. Cancer Res 1999;59:1861-68.

19. Croteau D, Scarpace L, Hearshe n D. Correlation between magnetic resonance spectroscopy imaging and image -guided biopsies: semiquantitative and qualitative histopathological analyses of patients with untreated glioma. Neurosurgery 2001;49(4):823-9.

20. Dowling C, Bollen AW, Noworolski SM. Preoperative proton MR spectroscopy imaging of brain tumors. Correlation with histopathologic analysis of resections specimens. AJNR 2001;22:604-12.

21. Watanabe M, Tanaka R, Takeda N. Magnetic resonance imaging and histopathology of cerebral gliomas. Neuro radiology 1992; 34:463-69.